Brief: Axcella Announces FDA Ind Clearance Of Axa1125 For Long Covid Fatigue
15/02/2023 22:42
Feb 15 (Reuters) - Axcella Health Inc AXLA.O :
* AXCELLA ANNOUNCES FDA IND CLEARANCE SUPPORTING REGULATORY
PATH
TO REGISTRATION OF AXA1125 FOR LONG COVID FATIGUE
* AXCELLA ANNOUNCES FDA IND CLEARANCE SUPPORTING REGULATORY
PATH
TO REGISTRATION OF AXA1125 FOR LONG COVID FATIGUE
* AXCELLA HEALTH INC - PHASE 2B/3 STUDY MAY PROCEED UNDER
U.S.
INVESTIGATIONAL NEW DRUG APPLICATION
* AXCELLA HEALTH INC: PHASE 2B/3 STUDY MAY PROCEED UNDER
U.S.
INVESTIGATIONAL NEW DRUG APPLICATION
* AXCELLA HEALTH INC: STUDY DESIGN NOW ACCEPTED BY U.S. AND
U.K.
REGULATORY AUTHORITIES
Source text for Eikon: ID:nBw6b98SKa
Further company coverage: AXLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Axcella Health
See all newsAxcella Health Inc expected to post a loss of $1.25 a share - Earnings Preview
Brief: Axcella Health Inc- On Oct 4, Co Received Notice From Nasdaq That Co Had Regained Compliance With Nasdaq
Brief: Axcella Announces Reverse Stock Split Effective September 19, 2023
U.S. STOCKS ON THE MOVE-PDD Holdings, Catalent, Best Buy
Brief: Axcella Granted Patent For Long Covid Fatigue Treatment